Responses
Best Oral Communications/Late-Breaking Abstracts 3 – Ovarian Cancer
Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab
Compose a Response to This Article
Other responses
No responses have been published for this article.